Interesting way to frame the vitiligo—as predicted—delay. Vitiligo was the indication with the biggest potential, and it’s delayed. May lead to faster overall profitability due to no rollout expense, but it hurts LT FCF by not profiting from the rollout sooner.
Also, FDA approval is no guarantee. FDA might not like the company’s response. No Go until Recell Go according to CEO.
Only 100 hospitals. No Go, uptake slow.
International: big sales without Go? I don’t think so, but at least the partnership is in place IF Go hopefully gets approved. Ease of use translates to slow rollout.
EPS beat with the caveat of Recell Go and Vitiligo delay. It’s bittersweet. I have to see Recell Go approval to believe it.
Ann: AVITA Medical Reports Third Quarter 2023 Results, page-4
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.96 |
Change
0.180(6.47%) |
Mkt cap ! $184.0M | |||
| Open | High | Low | Value | Volume |
| $2.88 | $3.02 | $2.85 | $1.215M | 413.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2499 | $2.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.98 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.98 |
Change
0.180 ( 8.35 %) |
||||
| Open | High | Low | Volume | ||
| $2.88 | $3.01 | $2.88 | 6348 | ||
| Last updated 15.51pm 08/05/2024 ? | |||||
| AVH (ASX) Chart |